Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlvotechHAM:Z45 +8.06%48 OCF Yield % is -11.04 as of Jul. 15, 2026. GuruFocus rates HAM:Z45 with a GF Score™ of 48/100 and a GF Value™ of €16.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Alvotech ranks worse than 88.08% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Alvotech OCF Yield % Related Terms
Alvotech OCF Yield % Historical Data
* Premium members only.
The historical data trend for Alvotech's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:Z45 vs PAHC, COLL, XERS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Alvotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (HAM:Z45) has a OCF Yield % of -11.04 as of Jul. 15, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Alvotech and its competitors. According to the industry distribution chart, Alvotech ranks #887 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Alvotech's OCF Yield % too high?
Alvotech's current OCF Yield % is -11.04. Based on the distribution chart, Alvotech ranks #887 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alvotech has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's OCF Yield % compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #887 out of 1007 companies for OCF Yield %. This places Alvotech in the lower half of its industry. The industry median OCF Yield % is 3.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.48, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Alvotech and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current OCF Yield % is -11.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €16.65, compared to a current price of €2.95 — trading 82.3% below its estimated fair value. The current OCF Yield % is -11.04. Alvotech's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current OCF Yield % is -11.04 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (HAM:Z45) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of €2.95 is trading 82.3% below its estimated GF Value™ of €16.65.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for HAM:Z45:
OCF Yield %: -11.04
GF Value™: €16.65 vs. price of €2.95 (82.3% below fair value)
No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
48GF Score
Get the complete analysis for HAM:Z45
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Z45 has been successfully added to your 
